Table 3.
Randomized, double-blind, placebo-controlled, phase IIb screening trials of sorafenib in HER2-negative advanced breast cancer

Progression-free survival was the primary endpoint.
aOne-sided p value.
Abbreviations: AC, Accelerated Community Oncology Research; CI, confidence interval; FM, Fondazione Michelangelo; HR, hazard ratio; NU, Northwestern University; SOLTI, Grupo Español de Estudio, Tratamiento y Otras Estrategias Experimentales en Tumores Sólidos.